{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:09:23Z","timestamp":1794938963030,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2314-B-195-018-MY3"],"award-info":[{"award-number":["114-2314-B-195-018-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-195-010, 114-2314-B-195-019"],"award-info":[{"award-number":["113-2314-B-195-010, 114-2314-B-195-019"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2320-B-038-007, 114-2314-B-038-136"],"award-info":[{"award-number":["114-2320-B-038-007, 114-2314-B-038-136"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004861","name":"Mackay Memorial Hospital","doi-asserted-by":"publisher","award":["MMH114-07"],"award-info":[{"award-number":["MMH114-07"]}],"id":[{"id":"10.13039\/501100004861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004861","name":"Mackay Memorial Hospital","doi-asserted-by":"publisher","award":["MMH114-08"],"award-info":[{"award-number":["MMH114-08"]}],"id":[{"id":"10.13039\/501100004861","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health and Welfare Surcharge of Tobacco Products","award":["MOHW110-TDU-B-212-144020, MOHW111-TDU-B-221-014013, MOHW112-TDU-B-221-124013, and MOHW113-TDU-B-221-134013"],"award-info":[{"award-number":["MOHW110-TDU-B-212-144020, MOHW111-TDU-B-221-014013, MOHW112-TDU-B-221-124013, and MOHW113-TDU-B-221-134013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00735-1","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:54:13Z","timestamp":1771001653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition"],"prefix":"10.1186","volume":"21","author":[{"given":"Jiunn-Chang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tun-Sung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Shu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsang-Pai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"735_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"735_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"735_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"735_CR4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3390\/cancers11111731","volume":"11","author":"A Rossetto","year":"2019","unstructured":"Rossetto A, De Re V, Steffan A, et al. Carcinogenesis and metastasis in liver: cell physiological basis. Cancers (Basel). 2019;11:1731.","journal-title":"Cancers (Basel)"},{"key":"735_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"735_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-2005-871200","volume":"25","author":"LR Roberts","year":"2005","unstructured":"Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005;25:212\u201325.","journal-title":"Semin Liver Dis"},{"key":"735_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54\u201363.","journal-title":"N Engl J Med"},{"key":"735_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on Sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"735_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"735_CR11","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S, et al. Donafenib versus Sorafenib in First-Line treatment of unresectable or metastatic hepatocellular carcinoma: A Randomized, Open-Label, Parallel-Controlled phase II-III trial. J Clin Oncol. 2021;39:3002\u201311.","journal-title":"J Clin Oncol"},{"key":"735_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after Sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282\u201396.","journal-title":"Lancet Oncol"},{"key":"735_CR14","doi-asserted-by":"publisher","first-page":"765101","DOI":"10.3389\/fimmu.2021.765101","volume":"12","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liu X, Liang J, et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects. Front Immunol. 2021;12:765101.","journal-title":"Front Immunol"},{"key":"735_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"735_CR16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"735_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/onco.13819","volume":"26","author":"MT Saung","year":"2021","unstructured":"Saung MT, Pelosof L, Casak S, et al. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist. 2021;26:797\u2013806.","journal-title":"Oncologist"},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352.","journal-title":"Lancet Oncol"},{"key":"735_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486\u2013541.","journal-title":"Cell Death Differ"},{"key":"735_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"735_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"735_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41418-022-00998-x","volume":"29","author":"A Balihodzic","year":"2022","unstructured":"Balihodzic A, Prinz F, Dengler MA, et al. Non-coding RNAs and ferroptosis: potential implications for cancer therapy. Cell Death Differ. 2022;29:1094\u2013106.","journal-title":"Cell Death Differ"},{"key":"735_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1046\/j.1365-2141.2003.04732.x","volume":"124","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114\u20137.","journal-title":"Br J Haematol"},{"key":"735_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/eci.12032","volume":"43","author":"C Datz","year":"2013","unstructured":"Datz C, Felder TK, Niederseer D, et al. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest. 2013;43:215\u201324.","journal-title":"Eur J Clin Invest"},{"key":"735_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1055-9965.EPI-13-0733","volume":"23","author":"A Fonseca-Nunes","year":"2014","unstructured":"Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk\u2013a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev. 2014;23:12\u201331.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"735_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41416-022-01998-x","volume":"128","author":"A Ajoolabady","year":"2023","unstructured":"Ajoolabady A, Tang D, Kroemer G, et al. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy. Br J Cancer. 2023;128:190\u2013205.","journal-title":"Br J Cancer"},{"key":"735_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12072-023-10593-y","volume":"18","author":"Y Mo","year":"2024","unstructured":"Mo Y, Zou Z, Chen E. Targeting ferroptosis in hepatocellular carcinoma. Hepatol Int. 2024;18:32\u201349.","journal-title":"Hepatol Int"},{"key":"735_CR28","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/cas.15378","volume":"113","author":"N Iseda","year":"2022","unstructured":"Iseda N, Itoh S, Toshida K, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 Inhibition in hepatocellular carcinoma. Cancer Sci. 2022;113:2272\u201387.","journal-title":"Cancer Sci"},{"key":"735_CR29","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to Sorafenib. Int J Cancer. 2013;133:1732\u201342.","journal-title":"Int J Cancer"},{"key":"735_CR30","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.","journal-title":"Elife"},{"key":"735_CR31","first-page":"6417","volume":"34","author":"E Lachaier","year":"2014","unstructured":"Lachaier E, Louandre C, Godin C, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34:6417\u201322.","journal-title":"Anticancer Res"},{"key":"735_CR32","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866\u20138.","journal-title":"Bioinformatics"},{"key":"735_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"J Zheng","year":"2021","unstructured":"Zheng J, Sato M, Mishima E, et al. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 2021;12:698.","journal-title":"Cell Death Dis"},{"key":"735_CR34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3390\/cancers2031441","volume":"2","author":"CM Bagi","year":"2010","unstructured":"Bagi CM, Andresen CJ. Models of hepatocellular carcinoma and biomarker strategy. Cancers (Basel). 2010;2:1441\u201352.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"735_CR35","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1755-8794-8-S2-S5","volume":"8","author":"B Chen","year":"2015","unstructured":"Chen B, Sirota M, Fan-Minogue H, et al. Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med Genomics. 2015;8(Suppl 2):S5.","journal-title":"BMC Med Genomics"},{"key":"735_CR36","doi-asserted-by":"crossref","unstructured":"Tsherniak A, Vazquez F, Montgomery PG et al. Defining a cancer dependency map. Cell. 2017; 170: 564\u2009\u2013\u200976.e16.","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"735_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","volume":"15","author":"WS Yang","year":"2008","unstructured":"Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234\u201345.","journal-title":"Chem Biol"},{"key":"735_CR38","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bmcl.2011.09.047","volume":"22","author":"M Weiwer","year":"2012","unstructured":"Weiwer M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012;22:1822\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"735_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.chembiol.2003.08.010","volume":"10","author":"Y Liu","year":"2003","unstructured":"Liu Y, Lashuel HA, Choi S, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003;10:837\u201346.","journal-title":"Chem Biol"},{"key":"735_CR40","doi-asserted-by":"publisher","first-page":"12020","DOI":"10.1021\/jacs.0c04527","volume":"142","author":"N Panyain","year":"2020","unstructured":"Panyain N, Godinat A, Lanyon-Hogg T, et al. Discovery of a potent and selective covalent inhibitor and activity-based probe for the deubiquitylating enzyme UCHL1, with antifibrotic activity. J Am Chem Soc. 2020;142:12020\u20136.","journal-title":"J Am Chem Soc"},{"key":"735_CR41","doi-asserted-by":"publisher","first-page":"D1633","DOI":"10.1093\/nar\/gkae1075","volume":"53","author":"T Liu","year":"2025","unstructured":"Liu T, Hwang L, Burley SK, et al. BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data. Nucleic Acids Res. 2025;53:D1633\u201344.","journal-title":"Nucleic Acids Res"},{"key":"735_CR42","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100\u201322.","journal-title":"Nat Protoc"},{"issue":"Suppl 1","key":"735_CR43","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1186\/1471-2105-12-S1-S33","volume":"12","author":"KC Hsu","year":"2011","unstructured":"Hsu KC, Chen YF, Lin SR, et al. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics. 2011;12(Suppl 1):S33.","journal-title":"BMC Bioinformatics"},{"key":"735_CR44","doi-asserted-by":"publisher","first-page":"101328","DOI":"10.1016\/j.redox.2019.101328","volume":"28","author":"G Miotto","year":"2020","unstructured":"Miotto G, Rossetto M, Di Paolo ML, et al. Insight into the mechanism of ferroptosis Inhibition by ferrostatin-1. Redox Biol. 2020;28:101328.","journal-title":"Redox Biol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00735-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:01:54Z","timestamp":1774026114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00735-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00735-1","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}